Kaposi Sarcoma Treatment segmentation by type classifies interventions into drug‑based, surgical, and radiation categories, each comprising distinct sub‑modalities that collectively define the market taxonomy. The drug‑based class, which includes chemotherapy, immunotherapy and targeted agents, dominates the revenue stream, representing roughly two‑thirds of total spend because of chronic administration requirements and higher unit pricing. Within this class, oral formulations (e.g., pomalidomide) and intravenous infusions (e.g., liposomal doxorubicin) generate differentiated cost structures and patient‑access pathways. The surgical type accounts for approximately 20 % of the market and is subdivided into excisional biopsy, laser ablation, and cryosurgery, each employed for localized cutaneous lesions where systemic therapy is unnecessary. Radiation therapy contributes the remaining 15 % and is split between external‑beam radiation therapy (EBRT) and brachytherapy, modalities selected based on lesion depth and anatomical constraints. By quantifying the relative contribution of each type, analysts can isolate pricing pressure points, assess procedural reimbursement trends, and forecast demand shifts driven by emerging minimally invasive technologies in the Kaposi Sarcoma Treatment market.
